ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2006
Survival in extra-orbital metastatic retinoblastoma:treatment results.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America.Bone marrow transplantation · 2012Trial
- Primary orbital rhabdoid tumour masquerading as atypical persistent foetal vasculature.BMJ case reports · 2024Article
- Clinical, Genomic, and Pharmacological Study ofCancers · 2020Article
- Global Retinoblastoma Presentation and Analysis by National Income Level.JAMA oncology · 2020Article
- Article
- Efficacy of second-course intra-arterial chemotherapy in children for advanced retinoblastoma recurrence after intra-arterial chemotherapy.Journal of interventional medicine · 2018Article
- Presenting signs of retinoblastoma at a tertiary level teaching hospital in Ethiopia.The Pan African medical journal · 2017Article
- Article
- Chemotherapy in Retinoblastoma: Current Approaches.Turkish journal of ophthalmology · 2015Review
- Management of retinoblastoma in children: current status.Paediatric drugs · 2015Review
- Retinoblastoma: achieving new standards with methods of chemotherapy.Indian journal of ophthalmology · 2015Review
- Development of retinoblastoma programs in Central America.Pediatric blood & cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetinoblastoma (RB) is the most frequent malignant eye tumor in childhood. In developing countries advanced stages are common. The purpose of this paper is to present our 21-year clinical experience with metastatic extra ocular RB patients treated with 5 different chemotherapy schemas at a single Mexican Pediatric referral center. MATERIALS AND
methodsA retrospective analysis was carried out reviewing the clinical characteristics of patients with metastatic RB. The information analyzed included the delay in diagnosis after first symptoms, age, sex, ocular staging, and anatomic site of metastases, treatment scheme, initial response and status at the last contact or date of death.
resultsEighty-one patients were included; age range was from 3 to 80 months. The most common site of metastasis was central nervous system (83.9%). From those patients treated with chemotherapy (n = 74), 89.2% presented a complete initial response (n = 66). Early mortality occurred in 7 cases before any treatment. Fifty-six received treatment and died with progressive disease. All patients without radiotherapy died with tumor activity (n = 15). The use of cisplatin was related with longer disease free intervals; no other variable was related with survival. Four patients were alive and disease free at 33 to 144.3 months of follow up from diagnosis. The prevalent cause of death was tumor progression.
conclusionsIn our experience, metastatic RB has a very high mortality rate in spite of the use of different chemotherapy regimens.
Indexed as
Identifiers
16632438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.